Form 8-K - Current report:
SEC Accession No. 0001140361-22-043061
Filing Date
2022-11-25
Accepted
2022-11-25 06:01:18
Documents
13
Period of Report
2022-11-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10044682_8-k.htm   iXBRL 8-K 34306
2 EXHIBIT 10.1 brhc10044682_ex10-1.htm EX-10.1 411265
  Complete submission text file 0001140361-22-043061.txt   640943

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20221123.xsd EX-101.SCH 3866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221123_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221123_pre.xml EX-101.PRE 16045
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10044682_8-k_htm.xml XML 4238
Mailing Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121
Business Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221417880
SIC: 2834 Pharmaceutical Preparations